KRX Transaction Reporting

Understand, validate and oversee Korea OTC derivatives reporting with confidence

Korea’s OTC derivatives reporting framework is designed to improve market transparency, strengthen supervisory oversight and support systemic risk management. It forms part of Korea’s response to the G20 commitment to require trade reporting of OTC derivatives, with the KRX Trade Repository serving as the central infrastructure for collecting, storing and managing reportable transaction data.

For firms in scope, the challenge is not just reporting to the trade repository. It is demonstrating that reportable transactions have been identified correctly, that source data is complete and accurate, and that the control framework around reporting can withstand regulatory scrutiny.

What is Korea Reporting?

Korea reporting refers to the obligation for certain firms and other in-scope entities to report OTC derivatives transaction information to the KRX Trade Repository. The FSC introduced the trade repository framework to improve transparency and stability in the OTC derivatives market, and KRX was designated as the trade repository for this purpose.

The KRX TR states that it centrally collects, stores and manages detailed information on OTC derivatives transactions, and uses the accumulated data to support market statistics and provide information needed by supervisory authorities.

The current framework covers interest rate, credit, foreign exchange, commodity and equity derivatives contracts.

Who is required to report under Korea reporting?

The FSC has said that the Korean reporting framework applies to:

• financial investment business entity

• Financial investment product clearinghouse   (CCPs)

Furthermore, although the following are not subject to reporting obligations, they can be granted access to the KRX Trade Repository (KRX‑TR) for the purpose of viewing and using trade information stored therein. Eligible users include the Financial Services Commission (FSC), the Financial Supervisory Service (FSS), the Bank of Korea (BOK), and counterparties to a reportable transaction.

Scope and Korean nexus

The Korean framework is aimed at improving transparency in the domestic OTC derivatives market, with reporting flowing into the KRX trade repository as the central market infrastructure. In practical terms, firms need to assess whether their OTC derivatives activity falls within the Korean reporting perimeter based on the applicable Korean rules, entity status and transaction profile.

For cross-border firms, that makes transaction mapping, entity scoping and booking-model analysis especially important, because reporting exposure can depend on who the reporting entity is and how the transaction sits within the Korean regulatory perimeter. This is an operational inference from the structure of the regime.

What must be reported?

According to the KRX TR, reportable information is grouped into four categories:

• trade information

• valuation information

• collateral information

• other information

The KRX TR explains that trade information includes, among other things:

• UTI

• input type, such as new / amendment / correction

• counterparty and reporting party information

• beneficiary, broker and calculation-agent information where relevant

• product classification information

• execution, confirmation and clearing-related information

In practice, firms need to control not only the core trade record, but also the surrounding reference, valuation and collateral data that supports reporting quality and supervisory use of the repository data.

Reporting deadlines

Korean OTC derivatives reporting is generally subject to a T+1 timeline, with specified derivatives contracts and subsequent changes needing to be reported within one business day of execution, termination or the relevant reportable change, subject to the detailed timing rules in the regulations.

However, where a financial investment business entity concludes a transaction at or after 18:00, the reporting deadline is extended to 24:00 on the second business day following the trade date.

The practical point is that firms need a reporting process that can identify reportable trades promptly, validate the data before submission and evidence that deadlines are being met consistently. This is an operational inference based on the existence of mandatory reporting and KRX validation processes.

Is Korea reporting single-sided, dual-sided or delegated?

The Korean framework is best described as a mandatory trade repository reporting regime rather than one usually summarised in marketing shorthand as purely single-sided or dual-sided. Where multiple in-scope entities have reporting obligations, firms need to analyse the Korean rules carefully to determine who is required to report and how operational responsibility is allocated. This is a cautious interpretation based on the available public materials.

For firms using service providers or internal reporting hubs, the key point remains the same: operational delegation does not remove the need for strong oversight of the quality and completeness of what is reported. That is an operational inference from the mandatory reporting model and KRX’s validation framework.

Are there Korea reporting exemptions or reliefs?

The publicly available English-language materials surfaced here focus mainly on the existence of the reporting obligation, the categories of firms in scope and the trade repository framework. They do not provide a simple consolidated public summary of exemptions in the same way some other jurisdictions do. Because of that, firms should assess any exemption, threshold or carve-out question directly against the current Korean rules and KRX reporting materials rather than assuming relief is available.

From a control perspective, the safest approach is to validate scope carefully and avoid relying on undocumented assumptions about exemption treatment.

Consequences of non-compliance

The FSC has expressly stated that firms subject to the Korean OTC derivatives reporting obligation may face fines of up to KRW 100 million for violating reporting requirements.

That makes reporting quality more than a back-office concern. For firms in scope, the expectation is that reportable transactions are identified properly, submitted through the required infrastructure, and supported by controls that can withstand regulatory review. This conclusion is supported by the FSC’s framing of the regime and KRX’s validation and data-consistency processes.

How En:ACT helps with Korea reporting oversight

En:ACT helps firms strengthen control over their Korea reporting obligations by ingesting raw transaction data from any source system, performing books and records reconciliation, and assessing 100% of transactions and fields against the applicable Korean reporting rules.

Using transparent, regulator-linked logic, the platform identifies:

• eligibility issues

• field-level errors

• cross-field inconsistencies

• missing identifiers

• reporting anomalies

• valuation and collateral data issues

Each identified issue is linked directly to the specific Korean reporting rule breached, giving firms a clear view of what is wrong, why it matters and where remediation is required.

En:ACT also ensures rules are kept up to date to reflect developments across:

• regulatory text

• regulator guidance

• consultation papers

• relevant industry papers

For Korea specifically, that means firms benefit from rule coverage maintained in line with the Korean OTC derivatives reporting framework and the KRX reporting model.

Specialist Korea expertise from the Novatus Intelligence team

Our Korea capability is supported by specialists within the Novatus Intelligence team, including SMEs with backgrounds across:

• banking

• asset management

• product

• regulation

For each regime, we align subject matter expertise to the specific rule set. In the case of Korea, that means access to specialists who understand the Korean OTC derivatives reporting framework, the KRX trade repository model and the practical control challenges firms face in maintaining reporting quality over time.

This combination of regulatory interpretation and operational experience helps clients move beyond basic compliance and build a reporting framework that is accurate, scalable and defensible.

‍

Common Korea reporting challenges

Some of the most common Korea reporting issues include:

• incomplete or inconsistent source data

• weak entity and scope mapping

• poor control over UTI and counterparty data

• inconsistent valuation or collateral reporting inputs

• field-level errors that only become visible when tested against related data

• limited transparency over the quality of what is actually submitted to the repository

In many cases, the issue is not a single bad field. It is the mismatch between the transaction as booked, the supporting data as held internally and the reportable record delivered to the repository. This is an operational inference consistent with KRX’s emphasis on validation and data consistency management.

‍

Why firms choose En:ACT for Korea reporting oversight

Firms use En:ACT because it gives them more than a validation tool. It provides a control framework around Korea reporting.

With En:ACT, firms can:

• test reporting quality against transparent rule logic

• reconcile source data to reported data

• identify issues before they become regulatory problems

• evidence oversight of internal or third-party reporting models

• benchmark reporting quality over time

• prepare for rule changes with greater confidence

The result is stronger reporting assurance, better governance and a clearer line of sight from raw transaction data to regulatory submission quality.

‍